



BY



SUCCESSSES AND UPGRADES of 2025

CLINICAL NEWS and PROGRESS

In 2025 ACUFREE confirmed its treatment efficacy by performing even better in “**REAL-LIFE**” therapies carried out in audiology centers than it did in 2023-24 in a top Hospital protected environment.

Hearing care professionals in Rome and Milan attained excellent improvement rates over several months of treatment, as measured with the THI international methodology.

- **34% average tinnitus reduction in the first 6 months** (peak improvement at 69%)
- **46% average tinnitus reduction after the first 6 months** (peak improvement at 87%)

COMMERCIAL NEWS and PROGRESS

At the end of 2025 ACUFREE secured a more advanced level of CE MARK MDR Certificate. This recognition enables full use of the Device and treatment in its latest more developed form in all European countries.

The EU MDR standard is, together with America’s FdA, the most prestigious and rigorous method in the World for assuring quality, safety and innovation of a medical device.

SCIENTIFIC NEWS and PROGRESS

1. **JPM** (*Journal of Personalized Medicine*) **peer-to-peer review**: this indexed international publication carries a **3.0 Impact Factor and a 4.1 Citation Rate**, making it a world-class scientific and clinical reference.
At the top of “Personalized Medicine” This JPM recognition extends beyond the ENT (acoustic) sector into “custom-made therapeutic solutions” for each patient – i.e. Personalized Medicine, which is seen as the future for healthcare.
2. **ACUFREE is the only TINNITUS MULTIPLE THERAPY (trimodal)**. This aggregate method and its results are considered “the way forward” for treating incurable diseases or disorders.
3. **ACUFREE is the only therapy with PHYSIOLOGICAL as well as PSYCHOLOGICAL effects!** Many other treatments have been trying to mask the symptoms for years but without managing to effectively adjust or remedy the neuro-acoustic region under treatment.
4. **PREVENTION**: assuring physiological effects, as against mere “perception of effects”, is the only true way of acting effectively against the degenerative nature of tinnitus.
5. **PERSISTENCE OF THE EFFECTS**: the “3-Month therapy” clinical results of 2023 were extended to 12 months in 2024 and showed an only minor drop of 11% in the average improvement rate. In 2025 in real-life treatments the rate of improvement raised significantly after 6 months; further evidence of ACUFREE’s progressive effect over time.

